Concurrent cetuximab and postoperative radiation in resected high‐risk squamous cell carcinomas of the head and neck: A single‐institution experience
暂无分享,去创建一个
N. Futran | E. Mendez | G. Laramore | J. Liao | L. Chow | U. Parvathaneni | C. Baik | K. Eaton | R. Martins | C. Rodriguez | M. Redman | R. Santana-Davila | Sylvia M. Lee | D. Araki | A. Bhrany | B. Goulart | Eduardo Mendez
[1] R. Gilbert,et al. Comorbidity and performance status as independent prognostic factors in patients with head and neck squamous cell carcinoma , 2016, Head & neck.
[2] I. Floriani,et al. Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826). , 2014 .
[3] C. Barrios,et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] B. Milleron,et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial , 2011, The Lancet.
[5] Robert P Takes,et al. Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. , 2010, Oral oncology.
[6] M. Socinski,et al. Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] G. Tortora,et al. EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.
[8] A. Schueler,et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Luiz Paulo Kowalski,et al. Comorbidity Is a Prognostic Factor in Elderly Patients with Head and Neck Cancer , 2007, Annals of Surgical Oncology.
[10] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[11] M. van Glabbeke,et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) , 2005, Head & neck.
[12] W. Hong,et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Baselga,et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. van Glabbeke,et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. , 2004, The New England journal of medicine.
[15] J. Jacobs,et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. , 2004, The New England journal of medicine.
[16] R. Weber,et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. , 2003, The New England journal of medicine.
[17] A. Huang,et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. , 1998, The New England journal of medicine.
[18] N. Maihle,et al. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. , 1994, International journal of radiation oncology, biology, physics.
[19] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[20] Jordi Giralt,et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.
[21] J. Ensley,et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.